Expression of Inflammatory Membrane Markers by Conjunctival Cells in Chronically Treated Patients with Glaucoma

Baudouin, Christophe; Garcher, Catherine Creuzot; Haouat, Nasser; Bron, Alain M.; Gastaud, P

doi:10.1016/s0161-6420(94)31322-4

Cited by 120 publications

(67 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence from animal studies and human tissue cell culture experiments, which suggests that preservatives can cause detrimental effects on the superficial ocular tissues, is supported by evidence from clinical studies (Wilson et al 1975;Lemp & Zimmerman 1988;Sherwood et al 1989;Herreras et al 1992;Baudouin et al 1994;Broadway et al 1994a;de Jong et al 1994;Kuppens et al 1995;Yalvac¸et al 1995;Aritu¨rk et al 1996;Baudouin 1996;Baudouin & de Lunardo 1998;Nuzzi et al 1998;Levrat et al 1999;Albietz & Bruce 2001;Eleftheriadis et al 2002;Dogan et al 2004;Pisella et al 2004;Kozobolis et al 2005;Manni et al 2005;Hong et al 2006). The key studies are outlined here and a full list of references is provided in Table 1.…”

Section: Toxicity Of Preservatives: Evidence From Clinical Studiesmentioning

confidence: 86%

“…Development of subconjunctival fibrosis without clinical signs of intolerance has frequently been documented in patients who have taken antiglaucoma medication for long periods of time (Baudouin et al 1994). The fibrosis is believed to result from an increase in the fibroblast density in the subepithelial substantia propria, linked with an increase in inflammatory cells (Sherwood et al 1989;Baudouin et al 1999).…”

Section: Conjunctiva and Corneamentioning

confidence: 99%

See 1 more Smart Citation

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

Baudouin

2008

Acta Ophthalmologica

Self Cite

234

146

View full text Add to dashboard Cite

ABSTRACT.Antiglaucoma medications are often associated with ocular adverse reactions such as dry eye, and burning or stinging sensations. These undesirable effects may lead to treatment discontinuation and reduced quality of life in patients with glaucoma. Antiglaucoma medications usually contain benzalkonium chloride (BAK) as a preservative. Animal studies, in vitro studies and in vivo experiments have demonstrated various adverse effects of BAK. Clinical studies have also shown an increased incidence of adverse events with BAK and have demonstrated that the withdrawal of preservatives reduces these effects. Collectively, these data suggest that preservative-free antiglaucoma treatments have clinically relevant benefits for patients.

show abstract

Section: Toxicity Of Preservatives: Evidence From Clinical Studiesmentioning

confidence: 86%

Section: Conjunctiva and Corneamentioning

confidence: 99%

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

Baudouin

2008

Acta Ophthalmologica

Self Cite

234

146

View full text Add to dashboard Cite

show abstract

“…С помощью од-ного из таких методов C. Baudouin продемонстри-ровал, что в мазках -отпечатках конъюнктивы пациентов с глаукомой, которые получают мест-ную медикаментозную терапию, имеет место бо-лее выраженная экспрессия провоспалительных антигенов HLA-DR и CD23 (низкоаффинного рецептора IgE). При этом взаимосвязи с тем или иным специфическим препаратом или комбинаци-ями антиглаукомных капель не выявлено [11].…”

Section: The Influence Of Local Iop-lowering Therapy On the Anterior unclassified

The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery

Petrov

Юрьевич²,

Lovpache

et al. 2017

Ophthalmology Reports

View full text Add to dashboard Cite

Nowadays, a wide choice of local IOP-lowering medications allows ensuring a successful intraocular pressure compensation and primary open angle glaucoma stabilization. However, taking into consideration a long term action of drugs on the ocular surface, even without clinical manifestations there is a direct inflammatory cells’ activation with mixed toxic and allergic changes, which is confirmed by histology, immune-histology, and impression cytology methods. Such chronic sub-clinical inflammation represent a potential risk of excessive fibroblast proliferation with subsequent rapid postoperative scarring of new outflow pathways and atypical filtration bleb formation. It is shown that there is a clear relationship between number of glaucoma drugs used, treatment duration, intensity of conjunctival infiltration with inflammatory cells and fibroblasts, and risk of episcleral fibrosis and subconjunctival scarring during post-op period. (For citation: Petrov SYu, Lovpache DzhN, Loskutov IA, Safronova DM. The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery. Ophthalmology Journal. 2017;10(4):41-47. doi: 10.17816/OV10441-47).

show abstract

“…46,48 Of note, adherence to treatment may depend on side-effects, but also on the frequency of instillation of the drops and the presence of preservative agents, the latter inducing a local reaction, that can have a negative effect on surgery, making the rate of success lower. 49 …”

Section: Dovepressmentioning

confidence: 99%

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Eyawo

Nachega

Lefèbvre

et al. 2009

OPTH

View full text Add to dashboard Cite

Background: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy. The relative efficacy of differing prostaglandin therapy is disputed. Methods: A meta-analysis was conducted of head-to-head randomized trials of prostaglandin therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence margins. Results: Our search identified 16 eligible trials, of which 15 were included in the meta-analysis. Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], -0.24 mmHg, 95% CI, -0.87 to 0.38, P = 0.45, I 2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I 2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, I 2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P  0.001, I 2 = 97%, 95% CI, 95 to 98, P  0.001). Five trials assessing latanoprost and bimatoprost revealed an elevated risk of conjunctival hyperemia with bimatoprost (RR 1.59, 95% CI, 1.02 to 2.48, P = 0.04, I 2 = 76%, 95% CI, 16 to 88, P = 0.002). Conclusion: Randomized head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy effects, but differing hyperemia effects.

show abstract

Expression of Inflammatory Membrane Markers by Conjunctival Cells in Chronically Treated Patients with Glaucoma

Cited by 120 publications

References 11 publications

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Contact Info

Product

Resources

About